Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
<h4>Background</h4>Personalized medicine is a growing area of research which aims to tailor the treatment given to a patient according to one or more personal characteristics. These characteristics can be demographic such as age or gender, or biological such as a genetic or other biomark...
Saved in:
| Main Authors: | Miranta Antoniou, Andrea L Jorgensen, Ruwanthi Kolamunnage-Dona |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0149803&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics
by: Josephine Bourner, et al.
Published: (2025-02-01) -
Allocating the Sample Size in Phase II and III Trials to Optimize Success Probability
by: Daniele De Martini
Published: (2014-11-01) -
Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.
by: Patrick P J Phillips, et al.
Published: (2019-03-01) -
Topical tacrolimus for the amelioration of breast cancer-related lymphedema (TACLE Trial): a study protocol for a randomized, double-blind, placebo-controlled phase II/III trial
by: Frederik Gulmark Hansen, et al.
Published: (2025-04-01) -
A randomized phase II/III trial of rosuvastatin with neoadjuvant chemo-radiation in patients with locally advanced rectal cancer
by: Prachi S. Patil, et al.
Published: (2025-03-01)